[go: up one dir, main page]

PE20241357A1 - Anticuerpo biespecifico anti-cldn4/anti-cd137 - Google Patents

Anticuerpo biespecifico anti-cldn4/anti-cd137

Info

Publication number
PE20241357A1
PE20241357A1 PE2023002906A PE2023002906A PE20241357A1 PE 20241357 A1 PE20241357 A1 PE 20241357A1 PE 2023002906 A PE2023002906 A PE 2023002906A PE 2023002906 A PE2023002906 A PE 2023002906A PE 20241357 A1 PE20241357 A1 PE 20241357A1
Authority
PE
Peru
Prior art keywords
variable region
cldn4
antibody
polynucleotide
bispecific antibody
Prior art date
Application number
PE2023002906A
Other languages
English (en)
Inventor
Yoshiyuki Tenda
Masatoshi Yuri
Shigenori Yagi
Yoshiki Satake
Kazunori Hirayama
Hiroki Shirai
Hiroki Sasaki
Fumiko Chiwaki
Masayuki Komatsu
Original Assignee
Astellas Pharma Inc
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Nat Cancer Ct filed Critical Astellas Pharma Inc
Publication of PE20241357A1 publication Critical patent/PE20241357A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a un anticuerpo biespecifico anti-CLDN4/anti-CD137, caracterizado porque comprende una region variable de la cadena pesada y una region variable de la cadena ligera de un anticuerpo anti-CLDN4, y una region variable de la cadena pesada y una region variable de la cadena ligera de un anticuerpo anti-CD137. Un polinucleotido que tiene una secuencia de nucleotidos que codifica una region variable de la cadena pesada o una region variable de la cadena ligera de un anticuerpo anti-CLDN4, y un polinucleotido que tiene una secuencia de nucleotidos que codifica una region variable de la cadena pesada o una region variable de la cadena ligera de un anticuerpo anti-CD137. Tambien se refiere a vector de expresion, caracterizado porque comprende el polinucleotido, una celula huesped que comprende dicho polinucleotido, un metodo para producir dicho anticuerpo biespecifico anti-CLDN4/anti-CD137, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
PE2023002906A 2021-04-22 2022-04-21 Anticuerpo biespecifico anti-cldn4/anti-cd137 PE20241357A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021072429 2021-04-22
PCT/JP2022/018350 WO2022224997A1 (ja) 2021-04-22 2022-04-21 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体

Publications (1)

Publication Number Publication Date
PE20241357A1 true PE20241357A1 (es) 2024-07-03

Family

ID=83722348

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002906A PE20241357A1 (es) 2021-04-22 2022-04-21 Anticuerpo biespecifico anti-cldn4/anti-cd137

Country Status (20)

Country Link
US (2) US12227586B2 (es)
EP (1) EP4327823A4 (es)
JP (2) JP7365654B2 (es)
KR (1) KR20230171465A (es)
CN (1) CN117222672A (es)
AR (1) AR125398A1 (es)
AU (1) AU2022262542A1 (es)
CA (1) CA3217637A1 (es)
CL (1) CL2023003100A1 (es)
CO (1) CO2023015630A2 (es)
CR (1) CR20230490A (es)
DO (2) DOP2023000230A (es)
EC (1) ECSP23087918A (es)
IL (1) IL307744A (es)
MX (1) MX2023012432A (es)
PE (1) PE20241357A1 (es)
SA (1) SA523451235B1 (es)
TW (1) TW202309083A (es)
WO (1) WO2022224997A1 (es)
ZA (1) ZA202310292B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250304706A1 (en) * 2022-05-12 2025-10-02 Astellas Pharma Inc. Anti-taa/anti-cd3 multispecific antibody
EP4606384A1 (en) * 2022-10-19 2025-08-27 Astellas Pharma, Inc. Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
KR100999844B1 (ko) 2006-07-19 2010-12-13 네오벌브 테크놀러지스 인크 고효율 방열 모듈을 구비한 고출력 ｌｅｄ 조명장치
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
KR101826224B1 (ko) 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
WO2014132647A1 (ja) * 2013-03-01 2014-09-04 公益財団法人ヒューマンサイエンス振興財団 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
TWI726842B (zh) * 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
BR112017020434A2 (pt) 2015-05-04 2018-06-26 Pieris Pharmaceuticals Gmbh polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EP3735463A4 (en) 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US12258378B2 (en) 2018-03-14 2025-03-25 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same
SG11202100172XA (en) 2018-07-12 2021-02-25 F Star Beta Ltd Antibody molecules that bind cd137 and ox40

Also Published As

Publication number Publication date
CO2023015630A2 (es) 2023-11-30
JP2023182689A (ja) 2023-12-26
BR112023021950A2 (pt) 2023-12-19
AR125398A1 (es) 2023-07-12
SA523451235B1 (ar) 2024-11-25
MX2023012432A (es) 2023-11-01
ECSP23087918A (es) 2023-12-29
IL307744A (en) 2023-12-01
CL2023003100A1 (es) 2024-03-22
JP7365654B2 (ja) 2023-10-20
EP4327823A4 (en) 2025-04-30
AU2022262542A1 (en) 2023-11-02
CN117222672A (zh) 2023-12-12
US12227586B2 (en) 2025-02-18
US20250154272A1 (en) 2025-05-15
DOP2023000230A (es) 2023-12-15
WO2022224997A1 (ja) 2022-10-27
CA3217637A1 (en) 2022-10-27
TW202309083A (zh) 2023-03-01
DOP2025000223A (es) 2025-10-15
ZA202310292B (en) 2025-03-26
JPWO2022224997A1 (es) 2022-10-27
EP4327823A1 (en) 2024-02-28
US20240209108A1 (en) 2024-06-27
KR20230171465A (ko) 2023-12-20
CR20230490A (es) 2023-11-16

Similar Documents

Publication Publication Date Title
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
CL2023002105A1 (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
PE20241349A1 (es) Anticuerpos de union a cd3
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
AR117727A1 (es) Anticuerpos que se unen a cd3
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
MX2017006626A (es) Cadenas ligeras comunes y metodos de uso.
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
MX2019005116A (es) Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
AR083293A1 (es) Agentes de union a cd33
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
PE20121563A1 (es) Anticuerpos que se unen especificamente al receptor epha2
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
PE20241357A1 (es) Anticuerpo biespecifico anti-cldn4/anti-cd137